Article
New-Generation Glucokinase Activators: Potential Game-Changers in Type 2 Diabetes Treatment
2023-12-13
Abstract excerpt
Achieving glycemic control and sustaining functional pancreatic β-cell activity remains an unmet medical need in the treatment of type 2 diabetes mellitus (T2DM). Glucokinase activators (GKAs) constitute a class of anti-diabetic drugs designed to regulate blood sugar levels and enhance β-cell function in patients with diabetes. A significant progression in GKA development is underway to address the limitations of...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 37099c8d-1e8f-5dbe-88ed-57951936e4be
- DOI
- 10.20944/preprints202312.0917.v1
